Medication vs Medication
Ozempic vs Wegovy
A practical UK comparison focused on what is genuinely different — not which brand has the loudest marketing.
Ozempic is licensed for type 2 diabetes. Wegovy is the semaglutide weight-management product. Do not treat the brand names as interchangeable.
Ozempic (context only)
Weight loss occurs, but Ozempic should not be presented as the UK licensed obesity brand/formulation
Wegovy injection
STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed
Side-by-side
| Ozempic (context only) | Wegovy injection | |
|---|---|---|
| Active ingredient | semaglutide | semaglutide |
| Form | Weekly injection | Weekly injection |
| Frequency | Once weekly | Once weekly |
| Licence | Type 2 diabetes licence — not a UK weight-management licence | UK weight management licence |
| NHS context | Diabetes treatment pathway, not an obesity-prescribing substitute for Wegovy | NICE-recommended in specialist weight-management pathways; access depends on pathway |
| Evidence | Strong diabetes evidence | Very strong |
| Weight-loss evidence | Weight loss occurs, but Ozempic should not be presented as the UK licensed obesity brand/formulation | STEP 1: mean -14.9% at 68 weeks with 2.4 mg; 7.2 mg is now a licensed maintenance option for adults with obesity if needed |
| Maintenance | Depends on diabetes indication and clinician plan | Long-term support/treatment matters; weight regain after stopping has been demonstrated |
| GI considerations | GI effects common | Common GI effects; dose escalation is used to improve tolerability |
Reasons to discuss Ozempic (context only)
- Semaglutide is an established molecule
- Strong diabetes evidence
- Useful clarification because many users confuse Ozempic and Wegovy
Trade-offs
- Not licensed in the UK as a weight-loss treatment
- Should not be ranked as a direct obesity-treatment purchase option
- Dose/formulation/indication differ from Wegovy
- Using it as shorthand for 'semaglutide for weight loss' creates confusion
Reasons to discuss Wegovy injection
- Large evidence base
- Weekly dosing
- Cardiovascular outcome evidence in appropriate populations
- 2.4 mg established; 7.2 mg injectable option now licensed for adults with obesity if needed
Trade-offs
- Injection
- GI effects
- The new 7.2 mg option should not be compared using old 2.4 mg-only trial assumptions
- NHS access remains pathway-limited
Which is stronger for weight loss?
Ozempic (context only) is rated 0/10 and Wegovy injection 8/10 in our comparison framework. That rating summarises the obesity evidence available for the licensed formulation; it is not a prediction of your result.
Which is easier to live with?
Ozempic (context only): Once weekly. Wegovy injection: Once weekly. For some people a weekly injection is easier than a daily tablet; for others avoiding a needle is decisive.
NHS vs private reality
Diabetes treatment pathway, not an obesity-prescribing substitute for Wegovy. NICE-recommended in specialist weight-management pathways; access depends on pathway. NICE criteria and NHS availability are related but not identical, so check the current pathway rather than assuming a clinically eligible medicine is immediately available through a GP.
Maintenance matters
Depends on diabetes indication and clinician plan. Long-term support/treatment matters; weight regain after stopping has been demonstrated. A treatment comparison that ends at the point of weight loss is incomplete.
Questions to ask a prescriber
- Which option is actually licensed and clinically appropriate for my health history?
- How do the expected benefits compare for someone with my diabetes/cardiovascular history?
- What side effects should make me contact you?
- What will monitoring involve?
- What is the plan if I cannot tolerate the maintenance dose?
- What happens if I stop?
Sources
Continue exploring